Background Relapses of multiple sclerosis decrease during pregnancy, when the hormone estriol is increased. Estriol treatment is anti-infl ammatory and neuroprotective in preclinical studies. In a small single-arm study of people with multiple sclerosis estriol reduced gadolinium-enhancing lesions and was favourably immunomodulatory. We assessed whether estriol treatment reduces multiple sclerosis relapses in women.
Introduction
Multiple sclerosis is an autoimmune, neurodegenerative disease of the CNS. 1 Relapses are decreased by more than 70% during the last trimester of pregnancy, 2 when oestrogen and progesterone concentrations are highest. 3 Pregnancy is a state of temporary immune modulation enabling survival of the fetus as a half-foreign allograft. 4 Other cell-mediated autoimmune diseases, such as psoriasis and rheumatoid arthritis, also improve during pregnancy. 5 Estriol is an oestrogen unique to pregnancy, made by the fetal-placental unit, and reaches highest concentrations in the last trimester. We postulated that increased concentrations of estriol might mediate a decrease in relapses. Preclinical studies of multiple sclerosis showed that estriol treatment has both anti-infl ammatory and neuroprotective properties, mediated through binding to oestrogen receptors expressed in the immune system and the CNS. 6 In a small phase 2, single-arm, crossover clinical trial 7 of estriol treatment for ten women with multiple sclerosis, monthly brain MRI showed signifi cant reductions in gadolinium-enhancing lesions during 6 months of treatment compared with 6 months before treatment. Peripheral blood mononuclear cells had signifi cantly increased expression of interleukin 5 and interleukin 10 and decreased concentrations of tumour necrosis factor (TNF) α and matrix metalloproteinase 9. 8, 9 When estriol treatment was discontinued for 6 months, both enhancing lesions and immune responses returned to pre-treatment levels. Furthermore, when estriol was administered again for 4 additional months, combined with a progestin for uterine protection, 10 the reduction in enhancing lesions and immunomodulation returned. [7] [8] [9] Estriol has been used for several decades throughout Europe and Asia for treating menopausal symptoms. [11] [12] [13] A Women's Health Initiative study 14 done in 2002 to assess whether premarin (a complex mix of conjugated oestrogens) protects against coronary heart disease in menopausal women aged 50-79 years was stopped prematurely because of an increased risk for cardiovascular disease and breast cancer, whereas the number of colorectal cancers and hip fractures decreased. Premarin includes estradiol, an oestrogen that is present at low concentrations in women with normal menstrual cycles and in oral contraceptives. Oral contraceptives have also been associated with cardiovascular risks in non-menopausal women, particularly in those who smoke. Whether oral contraceptives are a cause of breast cancer or if they enable breast cancer to be detected earlier is unclear. 15 The distinction between estradiol and estriol is important, because oestrogens are not all alike. 16 Estriol binds to ERα and ERβ weaker than does estradiol, and it binds to ERβ stronger than it does to ERα. 17 Oestrogenic eff ects on breast cancer and cardiovascular disease are mediated by ERα. Indeed, ERβ binding can antagonise ERα binding in some tissues, 17 with estriol treatment being protective in preclinical models of breast cancer. 18 Finally, estradiol also induces uterine endometrial proliferation, which can lead to cancer. 19 Thus, women taking oral contraceptives or hormone replacement therapy are not treated with unopposed oestrogens, 10 but rather in combination with a progestin to protect the uterus. 15 Estriol is a weaker stimulator of endometrial proliferation than is estradiol, such that it can be taken unopposed for up to a year, but after that, it too should be taken in combination with a progestin for uterine protection. 15 Here, we report results of a phase 2 clinical trial to test the safety and effi cacy of oral estriol as an add-on treatment in women with relapsing-remitting multiple sclerosis.
Methods

Study design and participants
We did this double blind, placebo-controlled, randomised, parallel group trial at 16 academic neurology clinics in the USA, starting on June 28, 2007 , with the last clinic visit on Jan 9, 2014, and last follow-up questionnaire on July 10, 2014. Eligible patients were women aged 18-50 years, with a diagnosis of relapsing-remitting multiple sclerosis according to the McDonald criteria, 20 a baseline score of 0-4·5 on the Expanded Disability Status Scale (EDSS), and relapsing disease activity in the previous 24 months. Key exclusion criteria were progressive multiple sclerosis, taking glatiramer acetate for more than 2 months before randomisation, currently smoking, and taking other concurrent disease-modifying or hormonal treatments (appendix pp 6-8). The study was approved by the ethics committee at each site and participants provided written informed consent at screening. The National Institutes of Health appointed a data and safety monitoring board, which monitored safety and effi cacy (appendix p 4) with representatives from the National Institutes of Health and the National Multiple Sclerosis Society serving as observing members. The protocol is available online.
Randomisation and masking
A statistician who had no further role in the trial randomly assigned patients (1:1) to receive oral estriol (8 mg daily) or oral placebo (matched by appearance and taste) using a computer-generated code with random permuted block design (block size six). We stratifi ed randomisation by glatiramer acetate treatment during screening, using Zelen's method 21 to ensure that treatment assignment was balanced within each clinic.
Patients, treating physicians, and all investigators assessing outcomes were masked to treatment assignment.
Research in context
Evidence before this study We searched PubMed for studies published between Jan 1, 1980, and June 25, 2015, with the terms "multiple sclerosis" and "estriol". We included clinical trials, clinical observations, and preclinical studies, both in vitro and in vivo in animals and human beings. We also searched abstracts from the American and the European Committees for Treatment and Research in Multiple Sclerosis from the past 5 years. Besides laboratory studies, we found one single-arm, crossover clinical trial of estriol for multiple sclerosis. ClinicalTrials.gov lists an ongoing double-blind, placebo-controlled trial of estriol treatment for relapsing-remitting and progressive multiple sclerosis with cognitive testing as the primary outcome (registration number NCT01466114).
Added value of this study
This study is the fi rst randomised, placebo-controlled trial of oral estriol treatment for women with relapsing-remitting multiple sclerosis to be completed. We showed the safety and benefi cial eff ects on relapse rates compared with placebo.
Implications of all the available evidence
These fi ndings are consistent with the hypothesis that increased concentrations of estriol during pregnancy might mediate, at least in part, the protective eff ect of pregnancy on relapse rates. A phase 3 study of estriol in relapsing-remitting multiple sclerosis is needed to test these fi ndings and to explore potential eff ects on disabilities.
For the protocol see http:// neurology.ucla.edu/media/ attachments/files/51/Estriol_ Relapse_Trial_Protocol.pdf
See Online for appendix Study statisticians and pharmacy staff were not masked to treatment, but they had no interaction with patients.
Procedures
All patients started glatiramer acetate injections (20 mg/day) within 2 months of randomisation. Patients provided their own glatiramer acetate. To avoid patients taking unopposed oestrogens, patients in the estriol group also received a progestin (norethindrone 0·7 mg) daily for 2 weeks every 3 months, starting at 6 months; patients in the placebo group received a second placebo matched to progestin. After 24 months of treatment, a 4-week taper began for both estriol and placebo (appendix p 21). Examining neurologists did the EDSS assessments, whereas treating neurologists managed patient care including treatment of relapses, and gynaecologists managed gynaecological issues. The appendix pp 9-14 shows details of the blood laboratory tests for safety, methods for measuring estriol blood concentration, MRI analyses of enhancing lesions 7 and brain volumes, 22, 23 and voxel-based morphometry for regional loss of grey matter.
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Outcomes
The primary endpoint was annualised confi rmed relapse rate at 24 months. A confi rmed relapse was defi ned as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 h in a participant who had been neurologically stable or improving in the previous 30 days, accompanied by an objective neurological change (worsening by 0·5 points on the EDSS or worsening by ≥1·0 points on the pyramidal, cerebellar, brainstem, or visual functional system scores), 25 not due to fatigue alone and not associated with fever or infection.
The secondary endpoints were time to fi rst confi rmed relapse, annualised relapse event rate, and time to fi rst relapse event, all at 24 months. A relapse event was defi ned as meeting the criteria for a confi rmed relapse without documentation of a change in EDSS score. Other prespecifi ed outcomes included safety, blood estriol concentration (at 3 months, 6 months, 12 months, 18 months, and 24 months), proportion of patients with confi rmed disability progression (defi ned as an increase of EDSS of ≥1·0 point in participants with baseline score of ≥1·0, or an increase of ≥1·5 points for those with a baseline score of 0, each sustained for at least 6 months), change from baseline in EDSS score, Modifi ed Fatigue Impact Scale (MFIS) score, Beck Depression Inventory (BDI) score, Multiple Sclerosis Quality of Life (MS QoL) score, Multiple Sclerosis Functional Composite (MSFC) score, and Paced Auditory Serial Addition Test (PASAT) score, as well as enhancing lesions, T2 lesions, and brain volume by MRI at 24 months.
All analyses were planned at 24 months, the end of the study. We also did analyses at 12 months. The National Institutes of Health would not fund a trial with a placeboonly comparator arm for this duration because approved treatments are available. However, because glatiramer acetate takes 9 months to reach full potency, 26 the fi rst 9 months of the study approximated a comparison of estriol only with placebo only, which could be captured by an analysis at 12 months.
We did post-hoc analyses of whole grey matter volume, cortical grey matter volume, white matter volume, PASAT scores stratifi ed by median PASAT score at baseline, brain volumes by MRI stratifi ed by presence or absence of enhancing lesions, proportion of patients with enhancing lesions, correlation of estriol concentration with relapses and with enhancing lesions, and correlation of PASAT scores with grey matter volumes (appendix pp 10,11).
Statistical analysis
We calculated that we would need a sample size of 150 patients to provide 80% power to detect a 33% reduction in relapse rates in the estriol group compared with the placebo group (0·75 in the estriol group vs 1·18 in the placebo group) at 24 months with a two-sided signifi cance level of 0·10. We assessed the diff erence in annualised confi rmed relapse rates between groups with a negative binomial regression model adjusted for age, baseline EDSS score (<2 vs ≥2), number of relapses in the 12 months before the study (≤1 vs >1), time since diagnosis (<1 vs ≥1 year), previous glatiramer acetate treatment (none vs previous or current), and previous interferon beta treatment (yes vs no). Annualised relapse rates included all events for the entire 24 months or those occurring until the last visit adjusted for the time for which the participant was in the study.
Phase 2 trials of relapsing-remitting multiple sclerosis often have a biomarker as their primary endpoint. By contrast, we used a clinical outcome for three reasons: the National Institutes of Health want to focus on relapses as a basis for powering a future phase 3 trial, pregnancy decreases relapses, 2 and a small phase 2 trial with monthly MRI scans has already been done. 7 Because this trial was phase 2, we used a signifi cance level of α=0·10 for all analyses, as has been used in cancer trials 27 and in phase 2 trials of stroke, 28 amyotrophic lateral sclerosis, 29 and Parkinson's disease. 30 The use of p<0·10 as signifi cant in phase 2 trials was considered stringent enough to assess the potential for clinical effi cacy of a new intervention, while controlling for false positives and avoiding the much higher costs of the larger sample sizes needed to achieve a p value of less than 0·05. 27, 28 For the analysis of time to fi rst relapse, we used Kaplan-Meier analysis and log-rank tests to estimate and compare the proportion of patients with fi rst relapse at each timepoint. We used a Cox proportional hazards model to compare the proportion of patients with relapse at 12 months and 24 months, adjusting for age, baseline EDSS score (<2 vs ≥2), number of relapses in the 12 months before the study (≤1 vs >1), duration of multiple sclerosis (<1 vs ≥1 year), previous glatiramer acetate treatment (never vs past or current), and previous interferon treatment (yes vs no). We used mixed eff ects models to analyse repeated measurement outcomes with the random eff ect of participant to account for within patient correlation. For the exploratory analyses of EDSS, PASAT, fatigue, depression, and quality of life, 31 we used a linear mixed eff ects model to compare treatment groups at 12 months and 24 months. We used a mixed eff ects negative binomial regression model and linear mixed eff ects model to compare enhancing lesion number and volume (log-transformed) between treatment groups at all follow-up visits, and a mixed eff ects logistic model to compare the number of participants with gadoliniumenhancing lesions, with a linear mixed eff ects model to compare the percentage change in brain volumes between treatment groups. We also used a mixed eff ects logistic regression model to assess the association between the number of enhancing lesions and the occurrence of relapses and estriol concentrations. Finally, we used a linear mixed eff ects model to assess the association between PASAT change and percentage brain volume change, between PASAT change and estriol concentration, and between compliance and estriol concentration. We did all the analyses for the intention-to-treat population, which included all patients who were enrolled and for whom data existed after taking at least one dose of study drug. The appendix shows details of the sensitivity analyses.
This study is registered with ClinicalTrials.gov, number NCT00451204.
Role of the funding source
None of the funding sources had any role in the collection, analysis, or interpretation of data, or writing of the article. The National Institutes of Health had a role Data are mean (SD) or n (%). EDDS=Expanded Disability Status Scale. *Selfreported. †Patients may have received more than one previous multiple sclerosis drug. ‡Scores on the EDSS ranged from 0 to 10, with higher scores indicating a greater degree of disability. §This patient had a score of 4·5 at the fi rst screening visit but 5·5 at baseline. Table 1 : Baseline characteristics of the intention-to-treat population in designing the study. All authors had full access to all of the data in the study. The corresponding author had fi nal responsibility for the decision to submit for publication.
Results
We screened 236 patients, 164 of whom we enrolled (fi gure 1). 158 participants received study drug and had at least one visit thereafter. Of the 158 patients, 82 were assigned to the estriol group and 76 were assigned to the placebo group. Baseline characteristics were balanced across groups ( After 24 months, the confi rmed relapse rate was 0·25 relapses per year (95% CI 0·17-0·37) in the estriol group versus 0·37 relapses per year in the placebo group (0·25-0·53), with an adjusted rate ratio of 0·63 (0·37-1·05; p=0·077; table 2, appendix p 22). The annualised relapse event rate was also reduced in the estriol group compared with the placebo group (table 2, appendix p 22). Time to confi rmed relapse was also signifi cantly lower in the estriol group than in the placebo group according to our threshold of p<0·1, but time to relapse event was not (fi gure 2, table 2). We had similar results for the exploratory analyses of data up to 12 months: the annualised confi rmed relapse rate was reduced in the estriol group compared with the placebo group, as were the annualised relapse event rate and the time to fi rst confi rmed relapse, but the time to fi rst relapse event did not diff er signifi cantly between groups (table 2, appendix p 22).
Estriol was well tolerated, with no substantial diff erences between groups in the number or proportion of patients with serious adverse events (table 3) . Laboratory abnormalities were the same in each group Probability of fi rst relapse event (95% CI) 40·5% (30·0-53·0) † 46·9% (35·9-59·3) † 0·70% (0·42-1·17) ¶ 0·179
At 12 months
Confi rmed relapse Annualised relapse rate (95% CI) 0·25 (0·16-0·40) 0·48 (0·33-0·69) 0·49 (0·28-0·88)* 0·016
Probability of fi rst relapse (95% CI)
Relapse event
Annualised relapse rate (95% CI) 0·33 (0·22-0·50) 0·61 (0·44-0·84) 0·52 (0·31-0·86)* 0·012
Probability of fi rst relapse event (95% CI)
The primary outcome was confi rmed relapse rate at 24 months; other analyses at 24 months were secondary and analyses at 12 months were exploratory. *Adjusted rate ratio. †Percentage of patients with relapse. ¶Adjusted hazard ratio. (data not shown). Irregular menses were more common in the estriol group than in the placebo group, whereas vaginal infections were less common (table 3) . We recorded no substantial diff erences in breast fi brocystic disease and no mammograms were positive for malignancy (table 3) . Uterine fi broids occurred in similar proportions in each group (table 3) . There was no substantial diff erence between groups in the number of patients with uterine endometrial thickness greater than 8 mm (table 3) . Finally, because oestrogen and progesterone can cause some irregularity in menstrual cycles, we used criteria for clinically relevant increased menstrual fl ow in an algorithm with uterine lining thickness to trigger a uterine endometrial lining biopsy (detailed in the protocol). There was little diff erence between treatment groups in the proportion of patients who had these biopsies ( signifi cantly decreased between 3 months and 24 months (data not shown), suggesting poor compliance as the reason for the diff erence. In a post-hoc analysis, we assessed compliance using pill counts and calendars and found strong correlations between estriol concentrations and compliance in the estriol group (regression coeffi cient 1·12 [SE 0·34]; p=0·001). Overall, compliance at 24 months was much the same in the estriol group (n=58; mean 0·88, SD 0·19; median 0·96, IQR 0·87-0·99) and the placebo group (n=55; mean 0·89, SD 0·13; median 0·94, IQR 0·84-0·99). Estriol concentration was inversely correlated with relapses (regression coeffi cient -0·21 [SE 0·11]; p=0·057), and gadolinium-enhancing lesions (-0·77 [SE 0·34]; p=0·028). We recorded signifi cant improvements with estriol compared with placebo for fatigue after 24 months (p=0·009; table 4). Cognitive testing as measured by PASAT showed no diff erences at 24 months; however, at 12 months, PASAT scores were signifi cantly greater in the estriol group than in the placebo group (table 4) , and in a post-hoc analysis of patients with a score of less than the median of 55 at baseline, improvements at 12 months were 4·7 points in patients who received estriol and 1·6 in patients who received placebo (p=0·011), whereas there was no signifi cant eff ect in patients with higher scores at baseline (p=0·694; table 4). We found no signifi cant diff erence for EDSS, depression score, MS QoL, or MSFC (table 4) . Because estriol concentrations were low at 24 months, which is when PASAT scores were no longer signifi cantly improved in the estriol group compared with the placebo group, we assessed correlations between estriol concentration and PASAT score. Estriol concentration was directly correlated with PASAT score (regression coeffi cient 0·36 [SE 0·17]; p=0·03). We recorded similar benefi ts of estriol treatment on 7/24 Spatial Recall cognitive testing (appendix p 16). Table 5 shows the results of prespecifi ed exploratory and post-hoc MRI outcomes. We recorded no diff erences between groups for the prespecifi ed endpoints related to enhancing or T2 lesions or whole brain volume. Post-hoc analyses showed a diff erence between groups at 12 months for cortical grey matter (p=0·056) and white matter (p=0·090). In patients without enhancing lesions at baseline, those in the estriol group had larger cortical grey matter volume than did those in the placebo group (p=0·043), whereas in patients who had enhancing lesions at baseline, those in the estriol group had smaller white matter volumes than did those in the placebo group (0·012). The appendix (p 24) shows localisation of the estriol treatment eff ect on grey matter by voxel-based morphometry.
Post-hoc analysis showed that cortical grey matter volume by MRI correlated directly with PASAT cognitive test improvement in estriol-treated participants (regression coeffi cient 0·82 [SE 0·38]; p=0·032), but not in placebotreated participants (regression coeffi cient -0·17 [SE 0·38]; p=0·660).
Discussion
Estriol treatment reduced relapse rates compared with placebo in patients with relapsing-remitting multiple sclerosis. The relapse rate ratio between the two groups was nearly the same as in the original sample size calculation; however, the relapse rates for both groups were considerably lower than expected. As a result, the power of the study was reduced to 74%, but the primary endpoint of a reduction in annualised confi rmed relapse rates at p<0·1 was reached. Our results suggest that estriol might have a role in decreased relapses during pregnancy.
Estriol is considered to be the safest oestrogen on the basis of data for its worldwide use for menopausal Mammogram with malignancy 0 0 0 0 NA Includes all patients who took at least one dose of study drug; however, the six patients who dropped out shortly after baseline visit did not have safety evaluation data and were excluded from the safety analysis. Laboratory abnormalities are only reported if they occurred in at least 5% of patients in either group. *All admitted to hospital, but none had severe or immediately life-threatening conditions. †Both patients in the estriol group discontinued the study, one before and one after 12 months; three patients in the placebo group discontinued the study, one before and two after 12 months. ‡This patient discontinued the study at the time of B-cell lymphoma diagnosis after being on the study for 12 months and died 17 months later. §Two patients had two biopsies each in the estriol group and two patients had three biopsies each in the placebo group; no abnormal proliferation was found. symptoms over 40 years. [11] [12] [13] The standard daily dose for menopause symptoms (2 mg) is generally lower than the dose we used, although some studies have used up to 16 mg. In this study, a dose of 8 mg induced an estriol concentration equivalent to that present early in the second trimester of pregnancy, consistent with previous fi ndings. 7 Because estriol concentrations continue to increase during pregnancy, the blood concentration induced by estriol treatment was below that usually present in the third trimester, when the eff ect of pregnancy in protection against relapse is greatest. 2 Even so, we postulated that the concentration achieved might be suffi cient to exert protective eff ects. We targeted second trimester levels to induce third trimester protection. This dose was safe and well tolerated, including in the uterus and breast. However, as is the case with all new drugs, the long-term eff ects will be unknown until larger and longer studies are done. Change from baseline at 12 months (estriol group n=69, placebo group n=62)
Change from baseline at 24 months (estriol group n=58, placebo group n=56) 5·1 (16·7), 3·9 (-2·4 to 12·2) 3·1 (13·8), 4·6 (-5·0 to 11·4) 2·2 (-2·3 to 6·8) 0·338
MS QoL-mental score ¶ Baseline (estriol group n=82, placebo group n=76) 80·7 (24·1), 86·3 (68·2 to 98·7) 83·5 (24·5), 92·9 (69·0 to 103·0)
Change from baseline at 12 months (estriol group n=69, placebo group n=62)
Change from baseline at 24 months (estriol group n=58, placebo group n=56)
MSFC score ¶ Baseline (estriol group n=82, placebo group n=76) -0·04 (0·69), 0·05 (-0·46 to 0·47) 0·06 (0·79), 0·24 (-0·44 to 0·75)
Change from baseline at 12 months (estriol group n=70, placebo group n=58) 0·12 (0·37), 0·09 (-0·06 to 0·29) 0·06 (0·38), 0·06 (-0·17 to 0·32) 0·07 (-0·05 to 0·20) 0·262
Change from baseline at 24 months (estriol group n=60, placebo group n=54) 0·10 (0·35), 0·09 (-0·06 to 0·29) 0·08 (0·43), 0·10 (-0·21 to 0·35) 0·03 (-0·10 to 0·16) 0·629
PASAT score ¶|| Baseline (estriol group n=82, placebo group n=76) 51·0 (8·9), 55 (45 to 58) 52·3 (9·1), 56 (49 to 59)
All patients
Change from baseline at 12 months (estriol group n=70, placebo group n=61) 1·93 (5·59), 1·0 (0·0 to 4·0) 0·13 (4·46), 0·0 (-1·0 to 2·0) 1·62 ( -0·03 to 3·27) 0·054
Change from baseline at 24 months (estriol group n=60, placebo group n=55) 1·07 (4·04), 1·0 (-1·5 to 3·0) 1·11 (4·29), 0·0 (-1·0 to 3·0) -0·11 (-1·81 to 1·60) 0·902
Patients with baseline score <55
Change from baseline at 12 months (estriol group n=33, placebo group n=25) 4·70 (6·56), 4·0 (2·0 to 6·0) 1·60 (5·99), 1·0 (0·0 to 5·0) 3·00 (0·68 to 5·32) 0·011
Change from baseline at 24 months (estriol group n=26, placebo group n=23) 2·31 (5·25), 3·5 (-3·0 to 6·0) 2·96 (5·88), 4·0 (-2·0 to 6·0) -0·33 (-2·74 to 2·07) 0·785
Patients with baseline score ≥55
Change from baseline at 12 months (estriol group n=37, placebo group n=36) -0·54 (2·88), 0·0 (-1·0 to 1·0) -0·89 (2·62), 0·0 (-1·5 to 0·5) 0·43 (-1·71 to 2·57) 0·694
Change from baseline at 24 months (estriol group n=34, placebo group n=32) 0·12 (2·47), 0·0 (-1·0 to 1·0) -0·22 (1·79), 0·0 (-1·0 to 1·0) 0·04 (-2·14 to 2·22) 0·971
All outcomes were exploratory, except for analysis of PASAT score above and below 55, which was post hoc. MS QoL=Multiple Sclerosis Quality of Life. PASAT=Paced Auditory Serial Addition Test. MSFC=MS Functional Composite. EDSS=Expanded Disability Status Scale. Data are mean (SD), median (IQR), unless stated otherwise. *Data are mean diff erence (95% CI) unless stated otherwise. †Calculated with the Kaplan-Meier product-limit method; progression defi ned as EDSS increase of at least 1·0 point in participants with a baseline score of 1·0 or higher, or an increase of at least 1·5 points in participants with a baseline score of 0, each sustained for at least 6 months. ‡Adjusted hazard ratio (95% CI), estimated by Cox proportional hazard regression; adjusted for age and baseline EDSS (<2 vs ≥2). §A negative change indicates improvement. ¶A positive change indicates improvement. ||To estimate the diff erence of PASAT score change between the two study groups for patients with baseline PASAT scores above or below the median, we included dichotomised baseline PASAT score (<55 vs ≥55) and its interaction terms with treatment and month in the model and all patients' follow-up data were used; p interaction =0·038 for 24 months, p interaction =0·092 for 12 months. The greater occurrence of irregular menses in the estriol group than in the placebo group was not surprising because oral contraceptives are known to cause menstrual irregularity, and estriol decreases vaginal fl ora and promotes urogenital health. 32, 33 If estriol was not safer than other oestrogens, the risk-to-benefi t Whole grey matter at 12 months -0·45 (0·77), -0·48 (-0·98 to -0·06) -0·71 (0·74), -0·68 (-1·20 to -0·16) 0·24 (-0·05 to 0·53) 0·106
Whole grey matter at 24 months -0·94 (0·81), -0·91 (-1·71 to -0·62) -0·99 (0·78), -0·93 (-1·56 to -0·35) 0·14 (-0·16 to 0·45) 0·358
Cortical grey matter at 12 months -0·39 (0·89), -0·43 (-0·97 to -0·01) -0·74 (0·84), -0·64 (-1·41 to -0·09) 0·34 (0·01 to 0·67) 0·043
Cortical grey matter at 24 months -0·96 (0·89), -0·98 (-1·91 to -0·54) -1·11 (0·89), -0·93 (-1·64 to -0·35) 0·29 (-0·06 to 0·63) 0·106
White matter at 12 months -0·19 (0·95), 0·06 (-0·69 to 0·41) -0·14 (0·72), -0·11 (-0·58 to 0·43) -0·10 (-0·48 to 0·28) 0·620
White matter at 24 months -0·41 (1·13), -0·35 (-0·93 to 0·09) -0·51 (1·18), -0·51 (-1·04 to 0·38) -0·00 (-0·40 to 0·39) 0·988 (Table 5 continues on next page) ratio of oral contraceptives and hormone replacement would be controversial in healthy individuals for whom no toxic eff ects are acceptable. However, for patients with a disabling disease such as multiple sclerosis, the risk-tobenefi t ratio is diff erent. Some patients who experienced menstrual irregularity might have then deduced their treatment allocation, but follow-up questionnaires did not suggest substantial unmasking. Furthermore, unmasking would not have aff ected the primary outcome because each relapse was confi rmed by an increase in the EDSS score as determined by an independent examiner who was not aware of adverse events.
Post-hoc MRI studies using volumetry at 12 months showed less cortical grey matter atrophy in the estriol group than in the placebo group. This eff ect was independently confi rmed by voxel-based morphometry to show which grey matter regions were preserved by treatment. Furthermore, patients in the estriol group without enhancing lesions had less cortical grey matter atrophy than did those in the placebo group, suggesting a direct neuroprotective eff ect independent from antiinfl ammatory eff ects, which is consistent with preclinical studies. 6 Cortical grey matter atrophy on brain MRI has been associated with cognitive dysfunction in patients with multiple sclerosis. 34, 35 In addition, oestrogen treatment improves cognitive dysfunction in women without multiple sclerosis who have had ovariectomy, 36 and oestrogen treatment of ovariectomised animals increases dendritic spines and synapses in cerebral grey matter. [37] [38] [39] We showed that higher serum estriol concentrations might be needed for benefi cial eff ects on cognition. Cortical grey matter sparing in the estriol group compared with the placebo group was lost at 24 months, when both estriol concentrations and PASAT scores had decreased. Indeed, we detected correlations between PASAT improvement and cortical grey matter sparing in all participants and in the estriol group, but not in the placebo group.
By contrast, patients in the estriol group with enhancing lesions had more white matter atrophy compared with those in the placebo group at both 12 months and 24 months, consistent with pseudoatrophy. 40 A pseudoatrophy or anti-infl ammatory eff ect in white matter in the estriol group would be consistent with the reduction in relapse rates. Whether maintenance of higher estriol concentrations at 24 months in all participants in the estriol group could have resulted in more robust eff ects on relapses or enhancing lesions is unknown. Achieving large reductions in these outcomes at 24 months compared with 12 months was challenging given: (1) the low level of relapse activity in this population, as shown by the few enhancing lesions at baseline, (2) the small sample size, and (3) the fact that all patients were treated with glatiramer acetate, which reduces relapse rates within 24 months of starting treatment. 26 Future studies with participants with more actively relapsing disease, a larger sample size, or placebo alone as a comparator would be necessary to test the eff ect of sustained concentrations of estriol.
Limitations of our study included the small sample size, requiring our fi ndings to be tested in a larger phase 3 study. Although treatment with estriol was safe and well tolerated for 24 months, assessing the long-term risk of treatment with estriol will require larger, longer studies, as well as post-marketing experience. Our fi ndings might encourage pilot trials for other Whole grey matter at 12 months -0·61 (0·84), -0·54 (-1·05 to -0·26) -0·65 (0·64), -0·64 (-1·08 to -0·15) 0·08 (-0·31 to 0·47) 0·698
Whole grey matter at 24 months -1·00 (0·68), -0·98 (-1·22 to -0·49) -0·83 (0·71), -0·92 (-1·25 to -0·28) -0·02 (-0·42 to 0·38) 0·923
Cortical grey matter at 12 months -0·60 (0·92), -0·57 (-1·10 to -0·26) -0·67 (0·72), -0·69 (-0·98 to -0·19) 0·08 (-0·37 to 0·53) 0·722
Cortical grey matter at 24 months -0·95 (0·85), -0·93 (-1·39 to -0·23) -0·82 (0·80), -0·93 (-1·29 to -0·27) 0·02 (-0·44 to 0·48) 0·919
White matter at 12 months -1·09 (1·03), -0·92 (-2·00 to -0·18) -0·36 (1·06), -0·13 (-0·69 to 0·16) -0·67 (-1·19 to -0·15) 0·012
White matter at 24 months -1·32 (1·31), -1·20 (-2·11 to -0·57) -0·62 (0·97), -0·84 (-1·47 to 0·24) -0·58 (-1·11 to -0·04) 0·034
Enhancing lesion volume and number, total T2 volume, and whole brain volume were exploratory outcomes. Because of the distribution of the data (with few patients having enhancing lesions), the most appropriate approach to assess enhancing lesion volume and number was to assess the proportion of patients with enhancing lesion activity. Whole grey matter, cortical grey matter, and white matter volumes, stratifi ed by patients with or without enhancing lesions at baseline, were post-hoc outcomes. *Data are mean diff erence (95% CI) except for number of enhancing lesions, which is mean of lesions number ratio (95% CI), and for proportion of patients with enhancing lesion on MRI, which is odds ratio (95% CI). †Negative change indicates improvement. ‡Negative change indicates worsening. §To estimate the diff erence of brain volume change between the two study groups for patients with and without enhancing lesions at baseline, we included baseline enhancing lesion number (present vs absent) in the model and used follow-up data for all patients; p interaction =0·058 for white matter at 12 months. cell-mediated autoimmune diseases that go into remission during pregnancy-ie, rheumatoid arthritis and psoriasis. However, estriol treatment should not be considered in primarily antibody-mediated autoimmune diseases such as lupus, since lupus tends to worsen during pregnancy. 5 Whether estriol treatment could be used in men with multiple sclerosis is unknown. Estriol treatment was protective in male mice in preclinical studies, 6 so it could also be effi cacious in men. However, because estriol treatment in men does not have the history of widespread use that treatment in women has, early phase safety studies are needed before its effi cacy in men with multiple sclerosis can be addressed. Although menstrual eff ects would not be an issue in men, breast enlargement or possibly other unexpected adverse events could occur.
In view of the current practice of aggressive treatment of relapsing-remitting multiple sclerosis to reduce disease activity as soon as possible after diagnosis, 41 a phase 3 trial of estriol in combination with glatiramer acetate is warranted. In addition, further studies are needed to investigate estriol for progressive multiple sclerosis given the neuroprotective eff ects of oestrogens, 6 and our promising exploratory fi ndings of sparing grey matter atrophy and improving cognition. Finally, because estriol is a simple biological molecule, it would be less expensive than many treatments 42 and more accessible to economically disadvantaged patients throughout the world.
